Document Detail


5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
MedLine Citation:
PMID:  7683354     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The preliminary results of a disease-oriented phase I-II study aimed at evaluating the clinical activity of 5-aza-2'-deoxycytidine (Decitabine) in patients affected by advanced myelodysplastic syndromes (MDS) are reported. Two patients affected by refractory anemia with excess of blasts (RAEB) and eight with RAEB in transformation (RAEB-T) were treated with Decitabine at a daily dose of 45 mg/m2, divided into three 4 h infusions for 3 days (six patients) or as continuous infusion of 50 mg/m2 for 3 days (four patients). Treatment with Decitabine resulted in a significant increase in circulating neutrophils, platelets, and hemoglobin with respect to pretreatment values in over 50% of patients. These changes were accompanied by the improvement of the marrow myeloid relative differentiation index (median fivefold increase in the whole group of patients) and of the myeloid to erythroid cell ratio (median twofold increase) in most of the patients. In four out of ten patients a complete normalization of peripheral blood (PB) and bone marrow (BM) picture (complete hematologic response) was obtained. The evaluation of the percentage of CD34-positive BM cells showed a slow but progressive reduction of early leukemic progenitors in most of the patients. A transient slight BM hypoplasia was obtained in less than 50% of patients while a severe marrow aplasia was never observed in our group of MDS patients during treatment with Decitabine. Extra-hematological toxicity was very mild in all the patients. The preliminary results of our study indicate that Decitabine is able to induce trilineage hematological responses in advanced MDS patients along with a stable normalization of the PB and BM picture in some of the subjects. Decitabine appears an active agent in advanced MDS and this deserves careful investigation in this heterogeneous group of disorders.
Authors:
V Zagonel; G Lo Re; G Marotta; R Babare; G Sardeo; V Gattei; V De Angelis; S Monfardini; A Pinto
Related Documents :
8010734 - Clinical application of serum levels of sialic acid, fucose and seromucoid fraction as ...
2772794 - Splenectomy for massive splenomegaly.
20010464 - Frequency of bcr-abl gene mutations in polish patients with chronic myeloid leukemia tr...
15059844 - Individualized risks of first adverse events in patients with fanconi anemia.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Leukemia     Volume:  7 Suppl 1     ISSN:  0887-6924     ISO Abbreviation:  Leukemia     Publication Date:  1993 May 
Date Detail:
Created Date:  1993-06-01     Completed Date:  1993-06-01     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8704895     Medline TA:  Leukemia     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  30-5     Citation Subset:  IM    
Affiliation:
Leukemia Unit, INRCCS, Aviano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anemia, Refractory, with Excess of Blasts / blood,  drug therapy*
Antigens, CD / analysis
Antigens, CD34
Azacitidine / analogs & derivatives*,  therapeutic use
Bone Marrow / pathology
Female
Humans
Male
Middle Aged
Remission Induction
Chemical
Reg. No./Substance:
0/Antigens, CD; 0/Antigens, CD34; 320-67-2/Azacitidine; 776B62CQ27/decitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  5-Aza-2'-deoxycytidine: cell differentiation and DNA methylation.
Next Document:  Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogen...